A growing area of medical research is examining the potential of fecal microbiota transplants (FMT) to address food allergies, which affect millions of Americans. Scientists are testing whether introducing healthy gut bacteria via oral capsules—often colloquially referred to as 'poop pills'—can alter the immune system's response to specific food triggers. The theory behind this treatment is that the gut microbiome plays a critical role in regulating immune responses; by diversifying the bacteria in a patient's digestive tract, researchers hope to reduce the severity of allergic reactions.

While the concept of fecal transplants has been used successfully to treat recurrent Clostridioides difficile infections, applying the method to food allergies is still in the experimental phase. Clinical trials are currently underway to assess both the safety and the long-term efficacy of this approach. Proponents of the research suggest that if successful, this could provide a transformative therapy for the nearly five million Americans living with peanut allergies. However, the medical community remains cautious, noting that the process requires rigorous screening of donors and standardized manufacturing to ensure patient safety. There is currently no consensus on the optimal bacterial composition required to 'cure' an allergy, and researchers emphasize that these treatments are not yet ready for general clinical use.